A phase 2 randomised controlled study of the therapeutic vaccine Nexvax2® is underway in Australian and New Zealand adults with HLA-DQ2·5 genotype positive coeliac disease. The epitope-specific immunotherapy which ‘reprograms’ T cells, suppresses inflammation and aims to increase the threshold for clinical reactivity to gluten in patients with coeliac disease. It offers patients the promise of ...
Vaccine for coeliac disease enters phase 2 trial
By Mardi Chapman
1 Nov 2018